First participant dosed in Jade’s Phase II JUNIPER trial for IgAN

Jade Biosciences has dosed the first participant in its Phase II JUNIPER clinical trial, evaluating JADE101 for IgAN. IgA nephropathy involves pathogenic IgA-containing immune complexes depositing in kidneys. Credit: superbeststock / Shutterstock.com. Jade Biosciences has dosed the first participant in its Phase II JUNIPER clinical trial, evaluating JADE101 for immunoglobulin A nephropathy (IgAN). The open-label trial aims to assess the antibody’s safety, tolerability, and efficacy in this chronic autoimmune kidney disease. LOA and PTSR Model Ianalumab in Lupus Nephritis Reports LOA and PTSR Model Ianalumab in Sicca Syndrome (Sjogren) Go deeper with GlobalData The gold standard of business…

Source: Clinical Trials Arena